2 Novo Nordisk, Financial Report for the Period 1 January 2024 to 31 December 2024, Company Announcement, February 5, 2025
Wegovy (semaglutide) is FDA-approved for chronic weight management in adults with obesity or overweight who have at least one weight-related condition, such as high blood pressure, type 2 diabetes, or high cholesterol
Two leading investigational therapies are attracting significant attention: MariTide (Maridebart Cafraglutide / AMG 133) Amgen Novel GLP-1 receptor agonist + GIP receptor antagonist Up to ~20% mean weight loss at 52 weeks in Phase 2 studies No weight-loss plateau observed at one year Currently advancing through the Phase 3 MARITIME program Potential for monthly or even less frequent administration PF-08653944 (Berobenatide) -Pfizer Ultra-long-acting GLP-1 receptor agonist Up to 12.3% placebo-adjusted weight loss at 28 weeks in Phase 2b Continued weight reduction after transition to monthly maintenance dosing No plateau observed at the 28-week analysis Designed to simplify long-term obesity management through monthly dosing Key Takeaway While MariTide currently leads in weight-loss efficacy, Pfizers Berobenatide highlights the potential of a streamlined, pure GLP-1 approach optimized for monthly maintenance and adherence
[7] [8] Certain probiotic strains have clinical evidence for constipation relief
Keep in mind SPF performance depends heavily on particle size, dispersion, and the rest of the formula, and not just the percentage
Once reconstituted, the vial lives in the refrigerator, never the freezer, since freezing a mixed solution can damage the peptide
